Answers are grounded in this paper and cite their sources.
To analyze the budget impact of upadacitinib (UPA) 15 mg + methotrexate (MTX) for the treatment of moderate-to-severe rheumatoid arthritis (RA) in patients with an inadequate response to conventional disease-modifying antirheumatic drugs (cDMARD-IR) from the perspective of social security and the private health sector in Argentina.
No takes yet. Share an insight, caveat, or question.
Espínola et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: